tbuckley/cabot-search huggingface dataset:
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma
Authors: Mwanasha H. Merrill, Parastoo B. Dahi, Robert A. Redd, Mikaela M. McDonough, Yi-Bin Chen, Zachariah DeFilipp, Alex F. Herrera, David C. Fisher, Ann S. LaCasce, Oreofe O. Odejide, Samuel Y. Ng, Caron A. Jacobson, Reid W. Merryman, Austin I. Kim, Yago L. Nieto, Craig S. Sauter, Gunjan L. Shah, Jasmine M. Zain, Philippe Armand, Eric D. Jacobsen
Journal: Blood (2023)
Orally delivered 2D covalent organic frameworks releasing kynurenine generate anti-inflammatory T cell responses in collagen induced arthritis mouse model
Authors: Madhan Mohan Chandra Sekhar Jaggarapu, Abhirami Thumsi, Richard Nile, Brian D Ridenour, Taravat Khodaei, Abhirami P Suresh, Arezoo Esrafili, Kailong Jin, Abhinav P Acharya
Journal: Biomaterials (2023)
How health technology reassessment can support disinvestment in China’s national drug reimbursement list
Authors: Lizheng Shi, Jiuhong Wu, Qingyue Meng, Dakui Li
Journal: BMJ (2023)

assess actual use of reimbursed medicines would enable transparent, documented, evidence based decisions on disinvestment, say Lizheng Shiand colleagues HTR=health technology reassessment, NMPA=National Medicine Product Administration, NHC=National Health Commission, NHSA=National Health Security Administration.*Low value was determined if there are better alternatives in the list; low use was determined by usage review for the reimbursement list.
Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments
Authors: James E. Barrett, Aryan Shekarabi, Saadet Inan
Journal: Pharmacological Reviews (2023)

Oxycodone, a semisynthetic derivative of naturally occurring thebaine, an opioid alkaloid, has been available for more than 100 years. Although thebaine cannot be used therapeutically due to the occurrence of convulsions at higher doses, it has been converted to a number of other widely used compounds that include naloxone, naltrexone, buprenorphine, and oxycodone. Despite the early identification of oxycodone, it was not until the 1990s that clinical studies began to explore its analgesic efficacy. These studies were followed by the pursuit of several preclinical studies to examine the analgesic effects and abuse liability of oxycodone in laboratory animals and the subjective effects in human volunteers. For a number of years oxycodone was at the forefront of the opioid crisis, playing a significant role in contributing to opioid misuse and abuse, with suggestions that it led to transitioning to other opioids. Several concerns were expressed as early as the 1940s that oxycodone had significant abuse potential similar to heroin and morphine. Both animal and human abuse liability studies have confirmed, and in some cases amplified, these early warnings. Despite sharing a similar structure with morphine and pharmacological actions also mediated by the μ-opioid receptor, there are several differences in the pharmacology and neurobiology of oxycodone. The data that have emerged from the many efforts to analyze the pharmacological and molecular mechanism of oxycodone have generated considerable insight into its many actions, reviewed here, which, in turn, have provided new information on opioid receptor pharmacology. SIGNIFICANCE STATEMENT: Oxycodone, a μ-opioid receptor agonist, was synthesized in 1916 and introduced into clinical use in Germany in 1917. It has been studied extensively as a therapeutic analgesic for acute and chronic neuropathic pain as an alternative to morphine. Oxycodone emerged as a drug with widespread abuse. This article brings together an integrated, detailed review of the pharmacology of oxycodone, preclinical and clinical studies of pain and abuse, and recent advances to identify potential opioid analgesics without abuse liability.
Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events
Authors: Takuto Takahashi, Mahmoud Al-Kofahi, Mutaz Jaber, Brandi Bratrude, Kayla Betz, Yvonne Suessmuth, Alison Yu, Donna S. Neuberg, Sung W. Choi, Jeffrey Davis, Christine Duncan, Roger Giller, Michael Grimley, Andrew C. Harris, David Jacobsohn, Nahal Lalefar, Nosha Farhadfar, Michael A. Pulsipher, Shalini Shenoy, Aleksandra Petrovic, Kirk R. Schultz, Gregory A. Yanik, Bruce R. Blazar, John T. Horan, Benjamin Watkins, Amelia Langston, Muna Qayed, Leslie S. Kean
Journal: Blood (2023)
Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck Cancer
Authors: Stéphanie Kermorgant
Journal: Journal of Clinical Oncology (2023)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. March 28, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00460 Journal of Clinical Oncology - published online before print June 15, 2023 PMID: 37319388 Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck Cancer Stéphanie Kermorgant, PhD1xStéphanie KermorgantSearch for articles by this author Show More 1Spatial Signalling Group, Barts Cancer Institute–a CR-UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, United Kingdom https://doi.org/10.1200/JCO.23.00460 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologySUPPORTSupported by Rosetrees Trust (M314 and M346), Barts Charity (MGU0511, G-001868, G-002205), and the MRC (MR/R009732/1).AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTRationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).No potential conflicts of interest were reported. Companion Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma
Authors: Laura K. Hilton, Henry S. Ngu, Brett Collinge, Kostiantyn Dreval, Susana Ben-Neriah, Christopher K. Rushton, Jasper C.H. Wong, Manuela Cruz, Andrew Roth, Merrill Boyle, Barbara Meissner, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Alina S. Gerrie, Ciara L. Freeman, Diego Villa, Judith A. Rodrigo, Kevin Song, Michael Crump, Lois Shepherd, Annette E. Hay, John Kuruvilla, Kerry J. Savage, Robert Kridel, Aly Karsan, Marco A. Marra, Laurie H. Sehn, Christian Steidl, Ryan D. Morin, David W. Scott
Journal: Journal of Clinical Oncology (2023)

Diffuse large B-cell lymphoma (DLBCL) is cured in more than 60% of patients, but outcomes remain poor for patients experiencing disease progression or relapse (refractory or relapsed DLBCL [rrDLBCL]), particularly if these events occur early. Although previous studies examining cohorts of rrDLBCL have identified features that are enriched at relapse, few have directly compared serial biopsies to uncover biological and evolutionary dynamics driving rrDLBCL. Here, we sought to confirm the relationship between relapse timing and outcomes after second-line (immuno)chemotherapy and determine the evolutionary dynamics that underpin that relationship.
Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer
Authors: Hannah M. Seagle, Samantha R. Keller, Sean V. Tavtigian, Carolyn Horton, Andreana N. Holowatyj
Journal: Journal of Clinical Oncology (2023)

The early-onset colorectal cancer (EOCRC) burden differs across racial/ethnic groups, yet the role of germline genetic predisposition in EOCRC disparities remains uncharacterized. We defined the prevalence and spectrum of inherited colorectal cancer (CRC) susceptibility gene variations among patients with EOCRC by race and ethnicity.
Rational Design and Efficacy of Glucose‐Responsive Insulin Therapeutics and Insulin Delivery Systems by Computation Using Connected Human and Rodent Models
Authors: Sungyun Yang, Jing Fan Yang, Xun Gong, Michael A. Weiss, Michael S. Strano
Journal: Advanced Healthcare Materials (2023)

Glucose-responsive insulins (GRIs) use plasma glucose levels in a diabetic patient to activate a specifically designed insulin analogue to a more potent state in real time. Alternatively, some GRI concepts use glucose-mediated release or injection of insulin into the bloodstream. GRIs hold promise to exhibit much improved pharmacological control of the plasma glucose concentration, particularly for the problem of therapeutically induced hypoglycemia. Several innovative GRI schemes are introduced into the literature, but there remains a dearth of quantitative analysis to aid the development and optimization of these constructs into effective therapeutics. This work evaluates several classes of GRIs that are proposed using a pharmacokinetic model as previously described, PAMERAH, simulating the glucoregulatory system of humans and rodents. GRI concepts are grouped into three mechanistic classes: 1) intrinsic GRIs, 2) glucose-responsive particles, and 3) glucose-responsive devices. Each class is analyzed for optimal designs that maintain glucose levels within the euglycemic range. These derived GRI parameter spaces are then compared between rodents and humans, providing the differences in clinical translation success for each candidate. This work demonstrates a computational framework to evaluate the potential clinical translatability of existing glucose-responsive systems, providing a useful approach for future GRI development.
Acute Respiratory Distress Syndrome Mediates the Association between Early Plasma Soluble Receptor for Advanced Glycation End Products Concentrations and Mortality in Sepsis
Authors: Tiffanie K. Jones, John P. Reilly, Brian J. Anderson, Todd A. Miano, Thomas G. Dunn, Alexandra P. Turner, Roseline S. Agyekum, Rui Feng, Caroline A. G. Ittner, Michael G. S. Shashaty, Nuala J. Meyer
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"Acute Respiratory Distress Syndrome Mediates the Association between Early Plasma Soluble Receptor for Advanced Glycation End Products Concentrations and Mortality in Sepsis." American Journal of Respiratory and Critical Care Medicine, 208(5), pp. 628–630
Photo‐Induced Electron Transfer‐Triggered Structure Deformation Promoting Near‐Infrared Photothermal Conversion for Tumor Therapy
Authors: Jingwei Pan, Jianjun Du, Qiao Hu, Yuan Liu, Xiaoxue Zhang, Xin Li, Danhong Zhou, Qichao Yao, Saran Long, Jiangli Fan, Xiaojun Peng
Journal: Advanced Healthcare Materials (2023)

Photothermal therapy (PTT) is a promising approach to cancer treatment. Heptamethine cyanine (Cy7) is an attractive photothermal reagent because of its large molar absorption coefficient, good biocompatibility, and absorption of near-infrared irradiation. However, the photothermal conversion efficiency (PCE) of Cy7 is limited without ingenious excitation-state regulation. In this study, the photothermal conversion ability of Cy7 is efficiently enhanced based on photo-induced electron transfer (PET)-triggered structural deformation. Three Cy7 derivatives, whose Cl is replaced by carbazole, phenoxazine, and phenothiazine at the meso-position (CZ-Cy7, PXZ-Cy7, and PTZ-Cy7), are presented as examples to demonstrate the regulation of the energy release of the excited states. Because the phenothiazine moiety exhibits an obvious PET-induced structural deformation in the excited state, which quenches the fluorescence and inhibits intersystem crossing of S1 →T1 , PTZ-Cy7 exhibits a PCE as high as 77.5%. As a control, only PET occurs in PXZ-Cy7, with a PCE of 43.5%. Furthermore, the PCE of CZ-Cy7 is only 13.0% because there is no PET process. Interestingly, PTZ-Cy7 self-assembles into homogeneous nanoparticles exhibiting passive tumor-targeting properties. This study provides a new strategy for excited-state regulation for photoacoustic imaging-guided PTT with high efficiency.
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group
Authors: Marinde J G Bond, Karen Bolhuis, Olaf J L Loosveld, Jan Willem B de Groot, Helga Droogendijk, Helgi H Helgason, Mathijs P Hendriks, Joost M Klaase, Geert Kazemier, Mike S L Liem, Arjen M Rijken, Cornelis Verhoef, Johannes H W de Wilt, Koert P de Jong, Michael F Gerhards, Martinus J van Amerongen, Marc R W Engelbrecht, Krijn P van Lienden, I Quintus Molenaar, Bart de Valk, Brigitte C M Haberkorn, Emile D Kerver, Frans Erdkamp, Robbert J van Alphen, Daniëlle Mathijssen-van Stein, Aysun Komurcu, Marta Lopez-Yurda, Rutger-Jan Swijnenburg, Cornelis J A Punt, Thomas Van Gulik, Joost Huiskens, Harm Van Tinteren, Cornelis H.C. Dejong, Dirk J. Grünhagen, Gijs A. Patijn, Theo J.M. Ruers, Thiery Chapelle, John J. Hermans, Wouter K.G. Leclercq, Liselot B.J. Valkenburg-van Iersel, Cecile Grootscholten, Joyce M. Van Dodewaard-de Jong, Jeroen Vincent, Danny Houtsma, Maartje Los, Marien Den Boer, Marija Trajkovic-Vidakovic, Theo Van Voorthuizen, Miriam Koopman, Johanneke H.M.J.V. Vestjens, Hans Torrenga, Leonie J. Mekenkamp, Gerrit Jan Veldhuis, Marco B. Polee, Serge E. Dohmen, Heidi Schut, Annelie J.E. Vulink, Henk K. Van Halteren, Jamal Oulad Hadj, Pieter-Paul J.B.M. Schiphorst, Ronald Hoekstra
Journal: The Lancet Oncology (2023)
Appeal from the European tuberculosis reference laboratory network (ERLTB-Net) for improving the diagnosis of infections due to nontuberculous mycobacteria
Authors: Elisa Tagliani, Thomas A. Kohl, Arash Ghodousi, Ramona Groenheit, Yen Holicka, Stefan Niemann, Florian P. Maurer, Daniela Maria Cirillo, Emmanuelle Cambau
Journal: Clinical Microbiology and Infection (2023)
Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells
Authors: Jinxiang Wang, Leli Zeng, Nisha Wu, Yanling Liang, Jie Jin, Mingming Fan, Xiaoju Lai, Zhe-Sheng Chen, Yihang Pan, Fangyin Zeng, Fan Deng
Journal: Drug Resistance Updates (2023)

Phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in the first step of the serine synthesis pathway (SSP), is overexpressed in multiple types of cancers. The androgen receptor inhibitor enzalutamide (Enza) is the primary therapeutic drug for patients with castration-resistant prostate cancer (CRPC). However, most patients eventually develop resistance to Enza. The association of SSP with Enza resistance remains unclear. In this study, we found that high expression of PHGDH was associated with Enza resistance in CRPC cells. Moreover, increased expression of PHGDH led to ferroptosis resistance by maintaining redox homeostasis in Enza-resistant CRPC cells. Knockdown of PHGDH caused significant GSH reduction, induced lipid peroxides (LipROS) increase and significant cell death, resulting in inhibiting growth of Enza-resistant CRPC cells and sensitizing Enza-resistant CRPC cells to enzalutamide treatment both in vitro and in vivo. We also found that overexpression of PHGDH promoted cell growth and Enza resistance in CRPC cells. Furthermore, pharmacological inhibition of PHGDH by NCT-503 effectively inhibited cell growth, induced ferroptosis, and overcame enzalutamide resistance in Enza-resistant CRPC cells both in vitro and in vivo. Mechanically, NCT-503 triggered ferroptosis by decreasing GSH/GSSG levels and increasing LipROS production as well as suppressing SLC7A11 expression through activation of the p53 signaling pathway. Moreover, stimulating ferroptosis by ferroptosis inducers (FINs) or NCT-503 synergistically sensitized Enza-resistant CRPC cells to enzalutamide. The synergistic effects of NCT-503 and enzalutamide were verified in a xenograft nude mouse model. NCT-503 in combination with enzalutamide effectively restricted the growth of Enza-resistant CRPC xenografts in vivo. Overall, our study highlights the essential roles of increased PHGDH in mediating enzalutamide resistance in CRPC. Therefore, the combination of ferroptosis inducer and targeted inhibition of PHGDH could be a potential therapeutic strategy for overcoming enzalutamide resistance in CRPC.
Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial
Authors: Bernhards Ogutu, Adoke Yeka, Sylvia Kusemererwa, Ricardo Thompson, Halidou Tinto, Andre Offianan Toure, Chirapong Uthaisin, Amar Verma, Afizi Kibuuka, Moussa Lingani, Carlos Lourenço, Ghyslain Mombo-Ngoma, Videlis Nduba, Tiacoh Landry N'Guessan, Guétawendé Job Wilfried Nassa, Mary Nyantaro, Lucas Otieno Tina, Piyoosh K Singh, Myriam El Gaaloul, Anne Claire Marrast, Havana Chikoto, Katalin Csermak, Ivan Demin, Dheeraj Mehta, Rashidkhan Pathan, Celine Risterucci, Guoqin Su, Cornelis Winnips, Grace Kaguthi, Bakary Fofana, Martin Peter Grobusch
Journal: The Lancet Infectious Diseases (2023)
The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity
Authors: Patricia Ho, Johannes C. Melms, Meri Rogava, Chris J. Frangieh, Joanna Poźniak, Shivem B. Shah, Zachary Walsh, Oleksandr Kyrysyuk, Amit Dipak Amin, Lindsay Caprio, Benjamin T. Fullerton, Rajesh Kumar Soni, Casey R. Ager, Jana Biermann, Yiping Wang, Mohsen Khosravi-Maharlooei, Giorgia Zanetti, Michael Mu, Hijab Fatima, Emily K. Moore, Neil Vasan, Samuel F. Bakhoum, Steven L. Reiner, Chantale Bernatchez, Megan Sykes, Emily M. Mace, Kai W. Wucherpfennig, Dirk Schadendorf, Oliver Bechter, Parin Shah, Gary K. Schwartz, Jean-Christophe Marine, Benjamin Izar
Journal: Cancer Cell (2023)
Acetate controls endothelial-to-mesenchymal transition
Authors: Xiaolong Zhu, Yunyun Wang, Ioana Soaita, Heon-Woo Lee, Hosung Bae, Nabil Boutagy, Anna Bostwick, Rong-Mo Zhang, Caitlyn Bowman, Yanying Xu, Sophie Trefely, Yu Chen, Lingfeng Qin, William Sessa, George Tellides, Cholsoon Jang, Nathaniel W. Snyder, Luyang Yu, Zoltan Arany, Michael Simons
Journal: Cell Metabolism (2023)
Investigating a possible link between antiseptic treatment and the increased occurrence of daptomycin-resistant Staphylococcus aureus
Authors: Andreas F. Wendel, Robin Otchwemah, Franziska Layer-Nicolaou, Frauke Mattner, Carlos J. Tellez-Castillo, Robert Skov, Henrik Oberländer, Guido Werner, Birgit Strommenger
Journal: Clinical Microbiology and Infection (2023)
Rapid diagnostic testing for syphilis in Arctic communities (the STAR study): a multisite prospective field diagnostic accuracy study in an intended-use setting
Authors: Chelsea Caya, Ameeta E. Singh, Bouchra Serhir, Veronique Morin, Michael D. Libman, Rachel Corsini, David M. Goldfarb, Tom Wong, Yiqing Xia, Mathieu Maheu-Giroux, Cedric P. Yansouni
Journal: Clinical Microbiology and Infection (2023)
Adaptability of single-nucleotide polymorphism-polymerase chain reaction (SNP-PCR) for subtyping SARS-CoV-2 and a new SNP-PCR for XBB, XBB.1.5, and B.Q.1/B.Q.1.1
Authors: Gordon Ritchie, Matthew Young, Natalie Prystajecky, Marc G. Romney, Christopher F. Lowe, Nancy Matic
Journal: Clinical Microbiology and Infection (2023)
Expanding evolutionary theories of ageing to better account for symbioses and interactions throughout the Web of Life
Authors: Eric Bapteste, Philippe Huneman, Laurent Keller, Jérôme Teulière, Philippe Lopez, Emma C. Teeling, Ariel B. Lindner, Annette Baudisch, William B. Ludington, Claudio Franceschi
Journal: Ageing Research Reviews (2023)
The Impact of Social Determinants of Health on Eye Care Utilization in a National Sample of People with Diabetes
Authors: Claudia Taccheri, Jalin Jordan, Diep Tran, Jiangxia Wang, Dingfen Han, Varshini Varadaraj, Deidra C. Crews, Cindy X. Cai
Journal: Ophthalmology (2023)

To evaluate the association of social determinants of health (SDoH) with eye care utilization among people with diabetes mellitus using the 2013-2017 National Health Interview Survey (NHIS).
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma
Authors: Yu Qian, Ana Galan-Cobo, Irene Guijarro, Minghao Dang, David Molkentine, Alissa Poteete, Fahao Zhang, Qi Wang, Jing Wang, Edwin Parra, Apekshya Panda, Jacy Fang, Ferdinandos Skoulidis, Ignacio I. Wistuba, Svena Verma, Taha Merghoub, Jedd D. Wolchok, Kwok-Kin Wong, Ralph J. DeBerardinis, John D. Minna, Natalie I. Vokes, Catherine B. Meador, Justin F. Gainor, Linghua Wang, Alexandre Reuben, John V. Heymach
Journal: Cancer Cell (2023)
Effects of vaginal microbiota transfer on the neurodevelopment and microbiome of cesarean-born infants: A blinded randomized controlled trial
Authors: Lepeng Zhou, Wen Qiu, Jie Wang, Aihua Zhao, Chuhui Zhou, Tao Sun, Ziyu Xiong, Peihua Cao, Wei Shen, Jingfen Chen, Xiaolu Lai, Liu-hong Zhao, Yue Wu, Meng Li, Feng Qiu, Yanhong Yu, Zhenjiang Zech Xu, Hongwei Zhou, Wei Jia, Yan Liao, Ravi Retnakaran, Daniel Krewski, Shi Wu Wen, Jose C. Clemente, Tianlu Chen, Ri-hua Xie, Yan He
Journal: Cell Host & Microbe (2023)
Signaling pathways driving ocular malignancies and their targeting by bioactive phytochemicals
Authors: Courtney R. Croley, Joshua Pumarol, Blake E. Delgadillo, Andrew C. Cook, Faith Day, Tea Kaceli, Caroline C. Ward, Imran Husain, Ali Husain, Sabyasachi Banerjee, Anupam Bishayee
Journal: Pharmacology & Therapeutics (2023)
The role of trained immunity in COVID-19: Lessons for the next pandemic
Authors: Mihai G. Netea, Athanasios Ziogas, Christine Stabell Benn, Evangelos J. Giamarellos-Bourboulis, Leo A.B. Joosten, Moshe Arditi, Konstantin Chumakov, Reinout van Crevel, Robert Gallo, Peter Aaby, Jos W.M. van der Meer
Journal: Cell Host & Microbe (2023)
Achieving integrated treatment: a realist synthesis of service models and systems for co-existing serious mental health and substance use conditions
Authors: Jane Harris, Sonia Dalkin, Lisa Jones, Tom Ainscough, Michelle Maden, Angela Bate, Alexandre Copello, Gail Gilchrist, Emma Griffith, Luke Mitcheson, Harry Sumnall, Elizabeth Hughes
Journal: The Lancet Psychiatry (2023)
HIV prevalence, risk behaviour, and treatment and prevention cascade outcomes among cisgender men, transgender women, and transgender men who sell sex in Zimbabwe: a cross-sectional analysis of programme data
Authors: Mariëlle Kloek, Sungai T Chabata, Laura van Noord, Fortunate Machingura, Rumbidzo Makandwa, Jeffrey Dirawo, Albert Takaruza, Primrose Matambanadzo, Sake J de Vlas, Jan A C Hontelez, Frances M Cowan
Journal: The Lancet HIV (2023)